Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | LIPA | P38571 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886845 | 0.89 | CYP19A1 (0.41) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL26357095 | 0.84 | MAPT (0.37) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL26356938 | 0.84 | MAPT (0.47) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL22733771 | 0.83 | MAPT (0.53) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL25251995 | 0.82 | MAPT (0.46) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL18698645 | 0.81 | MAPT (0.45) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL107668 | 0.81 | APOBEC3A (0.48) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL14907311 | 0.81 | MAPT (0.45) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL18373347 | 0.81 | APOBEC3A (0.48) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 | |
| SCHEMBL1552476 | 0.81 | MAPT (0.51) | MAPTAPOBEC3AAPOBEC3GHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8012620-A | — | — | None | — | — | JP | disclosed |
| WO-2020022089-A1 | ACTIVE LIGHT-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTIVE LIGHT-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN-FORMING METHOD, AND ELECTRONIC DEVICE PRODUCTION METHOD | 富士フイルム株式会社 | 2020-01-30 | — | — | WO | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-9867811-B2 | Method of treating atherosclerosis in high triglyceride subjects | NOVARTIS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-9867811-B2 | Method of treating atherosclerosis in high triglyceride subjects | NOVARTIS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-05-15 | — | — | US | disclosed |
| WO-2013047396-A1 | PATTERN FORMING METHOD, ELECTRON BEAM-SENSITIVE OR EXTREME ULTRAVIOLET-SENSITIVE COMPOSITION, RESIST FILM, METHOD FOR MANUFACTURING ELECTRONIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2013-04-04 | — | — | WO | disclosed |
| EP-2413191-A1 | Actinic-ray- or radiation-sensitive resin composition, resist film therefrom and method of forming pattern therewith | Fujifilm Corporation (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-8053161-B2 | Improved in line edge roughness not only in ordinary exposure (dry exposure) but also in immersion exposure | FUJIFILM CORPORATION (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20080081290-A1 | RESIST COMPOSITION, RESIN FOR USE IN THE RESIST COMPOSITION, COMPOUND FOR USE IN THE SYNTHESIS OF THE RESIN, AND PATTERN-FORMING METHOD USING THE RESIST COMPOSITION | FUJIFILM CORPORATION (JP) | 2008-04-03 | — | — | US | disclosed |
| JP-H0812620-A | SEPARATION OF STEREOISOMER OF ALKYL-SUBSTITUTED CYCLOHEXYL ESTER | MARUZEN PETROCHEM CO LTD | 1996-01-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | MAPT 4330/4885APOBEC3A 2866/4885APOBEC3G 2625/4885 |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | MAPT 4332/4885APOBEC3A 2917/4885APOBEC3G 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.